Tawen Chang
14 IP cases indexed. Covers patent matters.
Cases Presided Over
14 cases indexed | Page 1 of 1
Alamar Biosciences, Inc. v.Olink Proteomics AB et al.
The petitioner failed to prove the obviousness of claims 1-20 of U.S. Patent No. 7883848 in a Final Written Decision. The Board adopted a specific claim construction for 'selecting all cis-reactive cells exhibiting the detectable trace,' defining it as selecting associations of at least two interactor moieties joined by an associated oligonucleotide that exhibit the detectable trace.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
The PTAB issued a Final Written Decision rejecting all claims (1-19) of the '921 patent. The Board rejected arguments based on obviousness and novelty, particularly concerning multi-occupancy droplet detection in multiplexed biochemical assays.
Bruker Spatial Biology, Inc. v.10x Genomics, Inc. et al.
Bruker Spatial Biology successfully petitioned the PTAB to institute an IPR against 10x Genomics, Inc., challenging numerous claims of patent 11542554. The Board found a reasonable likelihood that the challenged claims are unpatentable based on grounds of obviousness (35 U.S.C. § 103).
Encube Ethicals Pvt. Ltd. v.Dermavant Sciences GmbH et al.
Encube Ethicals successfully challenged Dermavant Sciences' patent claims in the PTAB, leading to institution of the case. The Board found sufficient grounds for anticipation (102) and obviousness (103), specifically regarding psoriasis treatment methods. This decision significantly strengthens Encube's position by validating their prior art arguments against the '088 patent.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories, Inc. failed to institute an IPR against California Institute of Technology et al.'s patent covering multiplexed analyte detection. The Board found that the Petitioner did not provide sufficient support for key disclosures in the asserted prior art (Saxonov) during the initial petition phase.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories, Inc.'s IPR challenge against California Institute of Technology et al. was denied by the PTAB. The Board found that the Petitioner failed to demonstrate sufficient support for key prior art disclosures in Saxonov from the provisional application, leading to a failure to establish unpatentability under 35 U.S.C. 103(a).
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
The PTAB denied Bio-Rad Laboratories' request for rehearing regarding the denial of institution in IPR2024-01178, upholding its finding that the petitioner failed to meet the burden of proving unpatentability.
DR. FALK PHARMA GMBH v.Ellodi Pharmaceuticals LP
DR. FALK PHARMA GMBH challenged Ellodi Pharmaceuticals LP's '729 patent, asserting obviousness of claims related to orally disintegrating corticosteroids for GI tract inflammation. The PTAB declined to deny the petition, finding that additional evidence warranted reconsideration of prior art references like Dohil and FDA Guidance.
Bio-Rad Laboratories, Inc. v.California Institute of Technology et al.
Bio-Rad Laboratories successfully secured the institution of its IPR against California Institute of Technology's patent, challenging claims based on anticipation and obviousness. The Board found that Bio-Rad demonstrated a reasonable likelihood of prevailing regarding Claim 1 over Larson.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned the PTAB to institute an IPR against Merus N.V.'s patent (9358286) concerning heterodimeric Ig-like molecules. The Board found sufficient evidence of unpatentability under 35 U.S.C. §§ 102 and 103, advancing the dispute into the substantive review phase.
Xencor, Inc. v.Merus N.V.
Xencor, Inc. successfully petitioned to institute IPR against Merus N.V.'s patent (11926859) covering heterodimeric antibodies. The Board found reasonable likelihood of unpatentability based on written description and obviousness grounds.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.
Alamar Biosciences, Inc. v.Olink Proteomics AB et al.
Alamar Biosciences challenged Olink Proteomics' patent on grounds of obviousness (103), leading the PTAB to institute proceedings for claims 1-20. The Board found sufficient evidence that at least some claimed inventions are unpatentable, initiating a trial phase.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to institute IPR against Seikagaku Corporation's patent (11236318) based on grounds of lack of written description and obviousness. The Board found sufficient evidence at this preliminary stage, allowing the challenge to proceed into full litigation.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.